Starton Therapeutics advances STAR-LLD as delivery innovation in multiple myeloma
Starton Therapeutics advances STAR-LLD in Phase 2a. Explore how continuous lenalidomide delivery could reshape multiple myeloma care.
Pharma & Biotech
Pharma & Biotech
What Avidity Biosciences Phase 1/2 MARINA results reveal about the future of DM1 drug development
NEJM publication of Avidity Biosciences delpacibart etedesiran data raises new questions for DM1 treatment. Discover what this changes next.
Pharma & Biotech
Gilead expands its HIV playbook as lenacapavir moves from niche drug to platform strategy
Gilead’s CROI 2026 data highlight lenacapavir’s evolution into a platform for HIV treatment and prevention. Explore what this changes for clinicians and regulators.
Pharma & Biotech
What Omeros Corporation’s OncotoX-AML study reveals about mutation-agnostic AML therapies
Omeros Corporation advances OncotoX-AML after primate data. Explore what this means for AML therapy, risks ahead, and why clinicians are watching closely.
Pharma & Biotech
ViiV Healthcare’s Cabenuva and Dovato strategy looks like an ecosystem play as ultra long-acting candidates advance
ViiV Healthcare heads to CROI 2026 with ultra long-acting HIV data for VH4524184, VH4011499 and more. See what it changes next.
Pharma & Biotech
Why Harmony Biosciences’ pitolisant approval changes the risk calculus in pediatric narcolepsy
FDA approval expands pitolisant into pediatric cataplexy. Explore what this changes for narcolepsy care, safety, and long-term strategy.
Pharma & Biotech
How the Prostate Cancer Foundation’s $6.3m bet on young investigators could shape the next decade of prostate cancer innovation
Discover why the Prostate Cancer Foundation’s $6.3 million investment in young researchers could shape the future of prostate cancer diagnostics and treatment.
Pharma & Biotech
Why Watchmaker Genomics is repurposing CRISPR-Cas9 to reshape NGS library normalization at scale
Watchmaker Genomics is repurposing CRISPR-Cas9 to streamline NGS normalization. Find out why this matters for sequencing at scale.
Pharma & Biotech
Scribe Therapeutics deepens in vivo CRISPR validation with second Eli Lilly collaboration milestone
Scribe Therapeutics hits a second in vivo CRISPR milestone with Eli Lilly. Explore what this changes for gene editing platforms and future therapies.
Pharma & Biotech
Rallybio validates durable complement suppression with RLYB116 in Phase 1 study
Rallybio reports Phase 1 data for RLYB116 showing sustained complement inhibition. Find out what this changes for C5 therapies and what comes next.